METHOD FOR DETERMINING THE STAGE OF ATOPIC DERMATITIS Russian patent published in 2022 - IPC G01N33/68 G01N33/564 G01N33/573 

Abstract RU 2772411 C1

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to allergology and immunology, and can be used to determine the stage of atopic dermatitis. The inflammatory marker IL-36 is isolated in the patient’s blood serum by enzyme immunoassay. For this purpose, 100 mcl of sample dilution solution and 100 mcl of blood serum of a patient with atopic dermatitis are injected into the wells of the tablet. Incubating for 120 minutes while shaking on a shaker at a temperature of 37±1°С and 700 rpm and washing the tablet 5 times with a washing solution. After that, 100 mcl of the IL-36 inflammatory marker is introduced into the wells and incubated for 60 minutes when shaken on a shaker at a temperature of 37±1°С and 700 rpm. Then the tablet is washed 5 times with a washing solution and streptavidin-horseradish peroxidase is added to all wells and incubated for 30 minutes while shaking on a shaker at a temperature of 37±1°С and 700 rpm and wash the tablet 5 times with a washing solution. 100 ml of tetramethylbenzidine plus is introduced into the wells and incubated in a place protected from light for 25 minutes at a temperature from 18°C to 25°C. After adding the stop reagent to the wells of the tablet, the optical density of the solutions is measured on a vertical scanning spectrophotometer in the two-wave mode of 450 nm and 620 nm. With the values of the IL-36 inflammatory marker in the blood serum from 0.02 to 600 pg/ml, the stage of remission of atopic dermatitis is determined. With the values of the IL-36 inflammation marker in the blood serum from 601 pg/ml to 9800 pg/ml, the stage of exacerbation of atopic dermatitis is determined.

EFFECT: method provides an opportunity to increase the accuracy of determining the stage of atopic dermatitis, to give an objective assessment of it and to improve the diagnosis of this disease by determining the concentration of IL-36 in the patient’s blood serum, which is a specific marker of inflammation.

1 cl, 2 ex

Similar patents RU2772411C1

Title Year Author Number
METHOD FOR IMMUNOLOGICAL PREDICTION OF ACUTE CEREBRAL CIRCULATION DISORDERS 2023
  • Golikova Anna Sergeevna
  • Matveeva Liubov Vasilevna
  • Turkova Natalia Ivanovna
  • Al-Zakhar Nasser Badr Abdo
RU2820071C1
METHOD OF IMMUNOLOGICAL PREDICTION OF SUDDEN CORONARY DEATH 2023
  • Turkova Natalia Ivanovna
  • Matveeva Liubov Vasilevna
  • Golikova Anna Sergeevna
  • Al-Zakhar Nasser Badr Abdo
RU2810015C1
METHOD FOR PREDICTION OF SEVERITY OF ATOPIC DERMATITIS IN CHILDREN 2019
  • Bashkina Olga Aleksandrovna
  • Samotrueva Marina Aleksandrovna
  • Pakhnova Liya Ruslanovna
  • Tsibizova Aleksandra Aleksandrovna
  • Simonyan Artashes Mushegovich
  • Kokuev Aleksandr Viktorovich
RU2711746C1
GASTRIC CANCER IMMUNODIAGNOSIS METHOD 2023
  • Matveeva Liubov Vasilevna
  • Chudaikin Aleksandr Nikolaevich
  • Soldatova Anna Aleksandrovna
RU2818734C1
METHOD FOR IMMUNODIAGNOSIS OF STOMACH CANCER 2014
  • Matveeva Ljubov Vasilevna
  • Mosina Larisa Mikhajlovna
  • Stenina Marina Aleksandrovna
  • Soldatova Anna Aleksandrovna
RU2580309C1
PROGNOSIS METHOD OF UVEITIS DEVELOPMENT IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS 2016
RU2613056C1
METHOD FOR PREDICTION OF SEVERITY OF ATOPIC DERMATITIS IN CHILDREN 2017
  • Bashkina Olga Aleksandrovna
  • Pakhnova Liya Ruslanovna
  • Galimzyanov Khalil Mingalievich
  • Samotrueva Marina Aleksandrovna
  • Golubkina Svetlana Aleksandrovna
  • Kasymova Ekaterina Bashirovna
  • Ben Mbarek Makrem
RU2677481C1
METHOD OF TREATMENT OF ATOPIC DERMATITIS 2007
  • Kozhevnikov Vladimir Sergeevich
  • Barovskaja Natal'Ja Alekseevna
  • Korol'Kova Ol'Ga Jur'Evna
  • Nepomnjashchikh Vera Makarovna
  • Leonova Marina Ivanovna
  • Demina Dar'Ja Vladimirovna
RU2340348C1
METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 2021
  • Kostin Nikita Nikolaevich
  • Bobik Tatyana Vladimirovna
  • Skryabin Georgij Andreevich
  • Simonova Mariya Aleksandrovna
  • Balmasova Irina Petrovna
  • Abrikosova Viktoriya Aleksandrovna
  • Mokrushina Yuliana Anatolevna
  • Smirnov Ivan Vitalevich
  • Aleshenko Natalya Leonidovna
  • Nikitin Aleksej Eduardovich
  • Chekhonin Vladimir Pavlovich
  • Gabibov Aleksandr Gabibovich
RU2784655C1
METHOD FOR ASSESSING THE PROBABILITY OF DEVELOPING UNFAVORABLE HEART LEFT VENTRICULAR REMODELING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION 2021
  • Gusakova Anna Mikhailovna
  • Kercheva Mariia Anatolevna
  • Suslova Tatiana Evgenevna
  • Trubacheva Oksana Aleksandrovna
  • Riabova Tamara Rostislavovna
  • Riabov Viacheslav Valerevich
RU2770285C1

RU 2 772 411 C1

Authors

Pobezhimova Olga Olegovna

Zhestkov Aleksandr Viktorovich

Shtejner Mikhail Lvovich

Kulagina Vera Viktorovna

Lysov Nikolaj Aleksandrovich

Dates

2022-05-19Published

2021-09-22Filed